540 related articles for article (PubMed ID: 12882909)
1. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.
Miyazaki Y; He H; Mandarino LJ; DeFronzo RA
Diabetes; 2003 Aug; 52(8):1943-50. PubMed ID: 12882909
[TBL] [Abstract][Full Text] [Related]
2. Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise.
Beeson M; Sajan MP; Dizon M; Grebenev D; Gomez-Daspet J; Miura A; Kanoh Y; Powe J; Bandyopadhyay G; Standaert ML; Farese RV
Diabetes; 2003 Aug; 52(8):1926-34. PubMed ID: 12882907
[TBL] [Abstract][Full Text] [Related]
3. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.
Miyazaki Y; Mahankali A; Matsuda M; Glass L; Mahankali S; Ferrannini E; Cusi K; Mandarino LJ; DeFronzo RA
Diabetes Care; 2001 Apr; 24(4):710-9. PubMed ID: 11315836
[TBL] [Abstract][Full Text] [Related]
4. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.
Miyazaki Y; Glass L; Triplitt C; Matsuda M; Cusi K; Mahankali A; Mahankali S; Mandarino LJ; DeFronzo RA
Diabetologia; 2001 Dec; 44(12):2210-9. PubMed ID: 11793023
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone reverses insulin secretion altered by chronic exposure to free fatty acid via IRS-2-associated phosphatidylinositol 3-kinase pathway.
Yang L; An HX; Deng XL; Chen LL; Li ZY
Acta Pharmacol Sin; 2003 May; 24(5):429-34. PubMed ID: 12740178
[TBL] [Abstract][Full Text] [Related]
6. Insulin signal transduction in skeletal muscle from glucose-intolerant relatives of type 2 diabetic patients [corrected].
Storgaard H; Song XM; Jensen CB; Madsbad S; Björnholm M; Vaag A; Zierath JR
Diabetes; 2001 Dec; 50(12):2770-8. PubMed ID: 11723060
[TBL] [Abstract][Full Text] [Related]
7. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.
Bajaj M; Suraamornkul S; Romanelli A; Cline GW; Mandarino LJ; Shulman GI; DeFronzo RA
Diabetes; 2005 Nov; 54(11):3148-53. PubMed ID: 16249438
[TBL] [Abstract][Full Text] [Related]
8. Skeletal muscle insulin resistance in normoglycemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated insulin receptor substrate-1 tyrosine phosphorylation.
Pratipanawatr W; Pratipanawatr T; Cusi K; Berria R; Adams JM; Jenkinson CP; Maezono K; DeFronzo RA; Mandarino LJ
Diabetes; 2001 Nov; 50(11):2572-8. PubMed ID: 11679436
[TBL] [Abstract][Full Text] [Related]
9. Thiazolidinediones improve beta-cell function in type 2 diabetic patients.
Gastaldelli A; Ferrannini E; Miyazaki Y; Matsuda M; Mari A; DeFronzo RA
Am J Physiol Endocrinol Metab; 2007 Mar; 292(3):E871-83. PubMed ID: 17106061
[TBL] [Abstract][Full Text] [Related]
10. Thiazolidinedione treatment prevents free fatty acid-induced insulin resistance in male wistar rats.
Hevener AL; Reichart D; Janez A; Olefsky J
Diabetes; 2001 Oct; 50(10):2316-22. PubMed ID: 11574414
[TBL] [Abstract][Full Text] [Related]
11. Dissociation between fat-induced in vivo insulin resistance and proximal insulin signaling in skeletal muscle in men at risk for type 2 diabetes.
Storgaard H; Jensen CB; Björnholm M; Song XM; Madsbad S; Zierath JR; Vaag AA
J Clin Endocrinol Metab; 2004 Mar; 89(3):1301-11. PubMed ID: 15001626
[TBL] [Abstract][Full Text] [Related]
12. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y; Mahankali A; Matsuda M; Mahankali S; Hardies J; Cusi K; Mandarino LJ; DeFronzo RA
J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
[TBL] [Abstract][Full Text] [Related]
13. Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerance and type 2 diabetes mellitus. A pilot study of rosiglitazone.
Osei K; Gaillard T; Schuster D
Metabolism; 2007 Jan; 56(1):24-9. PubMed ID: 17161222
[TBL] [Abstract][Full Text] [Related]
14. Effects of exercise and insulin on insulin signaling proteins in human skeletal muscle.
Koval JA; Maezono K; Patti ME; Pendergrass M; DeFronzo RA; Mandarino LJ
Med Sci Sports Exerc; 1999 Jul; 31(7):998-1004. PubMed ID: 10416561
[TBL] [Abstract][Full Text] [Related]
15. Rosiglitazone ameliorates abnormal expression and activity of protein tyrosine phosphatase 1B in the skeletal muscle of fat-fed, streptozotocin-treated diabetic rats.
Wu Y; Ouyang JP; Wu K; Wang SS; Wen CY; Xia ZY
Br J Pharmacol; 2005 Sep; 146(2):234-43. PubMed ID: 15997237
[TBL] [Abstract][Full Text] [Related]
16. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.
Yu JG; Javorschi S; Hevener AL; Kruszynska YT; Norman RA; Sinha M; Olefsky JM
Diabetes; 2002 Oct; 51(10):2968-74. PubMed ID: 12351435
[TBL] [Abstract][Full Text] [Related]
17. Ursolic acid and rosiglitazone combination improves insulin sensitivity by increasing the skeletal muscle insulin-stimulated IRS-1 tyrosine phosphorylation in high-fat diet-fed C57BL/6J mice.
Sundaresan A; Radhiga T; Pugalendi KV
J Physiol Biochem; 2016 Jun; 72(2):345-52. PubMed ID: 27090933
[TBL] [Abstract][Full Text] [Related]
18. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
Triplitt C; Glass L; Miyazaki Y; Wajcberg E; Gastaldelli A; De Filippis E; Cersosimo E; DeFronzo RA
Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
[TBL] [Abstract][Full Text] [Related]
19. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability.
Oakes ND; Thalén PG; Jacinto SM; Ljung B
Diabetes; 2001 May; 50(5):1158-65. PubMed ID: 11334421
[TBL] [Abstract][Full Text] [Related]
20. Dose-response effect of elevated plasma free fatty acid on insulin signaling.
Belfort R; Mandarino L; Kashyap S; Wirfel K; Pratipanawatr T; Berria R; Defronzo RA; Cusi K
Diabetes; 2005 Jun; 54(6):1640-8. PubMed ID: 15919784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
